Observed Signal · Jul 2, 2026 · Industry Commentary · Source: The Drum · Impact: 2/5 · Sentiment: Positive
Pharma as Model for AI in Regulated Marketing
At Cannes Lions, Tom Richards (global chief creative officer at 21GRAMS, part of Real Chemistry) and Camilla Griffiths (president for Europe at 21GRAMS) told The Drum that the pharmaceutical sector offers a useful blueprint for marketing with AI under tight regulation. They argue that regulatory constraints can sharpen creative briefs and that involving compliance, legal and regulatory teams from the start produces better work. They also warn that AI changes how audiences discover health information — calling AI “an audience in and of itself” — and that brands must prioritise trustworthy, useful guidance to help empowered patients navigate conflicting online advice. The pair suggest healthcare’s regulated experience can help other industries adapt to AI, trust and scrutiny in marketing.
Provides industry insight showing how heavily regulated sectors (pharma) can serve as a practical blueprint for marketers using AI under tightened regulation; useful but not industry-shifting.
MARKET SIGNALS
Track Regulation Signals & Market Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Key Takeaways & Evidence Grounding
- Tom Richards is global chief creative officer at 21GRAMS (part of Real Chemistry).
- Camilla Griffiths is president for Europe at 21GRAMS.
- At Cannes Lions they said pharma can be a 'poster boy' for working with AI under regulation.
- They recommend involving compliance, legal and regulatory teams from the beginning of healthcare campaigns.
- They described AI as 'an audience in and of itself' and urged brands to provide trustworthy information as patients become more empowered.
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Cannes: AI Search Crisis Is Really Brand Coherence
At Cannes Lions 2026, industry conversations shifted from creative execution to how brands appear, are trusted, and recommended by LLMs and AI-driven search systems. Speakers and executives argued that large language models synthesize signals from SEO, PR, content and product pages into a single, machine-read ‘truth,’ exposing inconsistencies across functions. Practitioners say the challenge is coordination and organisational change — not just SEO tactics — because LLMs prioritise machine-readable authority, citations and trust signals. Boston Consulting Group data cited at the festival found 96% of 300 CMOs believe AI is transforming marketing, but only about a third have rebuilt workflows or operating models. Panelists urged governance, cross-functional alignment, and new measurement approaches so brands can be both persuasive to people and legible to AI systems.
Brands Set Rules for AI in Customer-Facing Content
Brands are rapidly adopting generative AI to accelerate creative production, remix existing assets, lower costs and enable concepts impractical to film, while enforcing brand-specific guardrails for consumer-facing content. Case studies from Unilever, Hilton, Koia, Coca‑Cola and smaller brands show faster asset turnaround and measurable performance gains, but marketers emphasize AI should refine—not replace—human creativity to avoid “sameness,” authenticity risks and potential consumer backlash. Teams distinguish behind-the-scenes uses (drafting, optimization, localization) from visible AI outputs (AI-generated people), with some brands limiting public-facing AI to protect trust or premium positioning. Surveys underline near-universal marketer adoption—Canva found most leaders use AI daily and plan to increase investment—so companies pair AI-driven scale with policies and creative oversight to preserve brand voice.
Agentic AI Transforming Pharma Marketing for Rare Diseases
This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.
WATCHLIST & BRIEFINGS
Receive future signals for Regulation in your Watchlist briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor Regulation
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
